ProfileGDS5678 / 1426957_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 84% 83% 82% 81% 81% 87% 84% 84% 85% 84% 84% 82% 83% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.1805584
GSM967853U87-EV human glioblastoma xenograft - Control 26.129283
GSM967854U87-EV human glioblastoma xenograft - Control 35.9234482
GSM967855U87-EV human glioblastoma xenograft - Control 45.9430981
GSM967856U87-EV human glioblastoma xenograft - Control 55.8853281
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.3868487
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.1305784
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1317584
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.2991785
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.2688984
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.1435684
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.9464482
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.1288283
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0496483